Undisclosed VRK1 inhibitor / Tango Therap - LARVOL DELTA

VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cells (AACR 2026) - "Furthermore, in vivo tolerability studies suggest that VRK1 inhibitors are well-tolerated in immunocompromised mice. Preclinical validation studies support the development of VRK1 inhibitors for the treatment of patients with VRK2-deficient tumors such as glioblastoma and neuroblastoma."

Synthetic lethality • Brain Cancer • Glioblastoma • Neuroblastoma • Oncology • Solid Tumor

Investigating VRK1 inhibition as an anti-cancer therapy for pancreatic ductal adenocarcinoma (AACR 2025) - "This protocol will serve as a launching point to validate the discovery of VRK1 inhibitors from a 12,000-compound kinase assay screen. Elucidation and understanding of when VRK1 inhibition activate/induces the cGAS-STING pathway and cellular senescence, may provide the rational for to pursuing of VRK1 inhibitors as novel therapeutics for the treatment of PDAC."

Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor